Stemedica - PRWeb Press Release Group

Stemedica Neural Stem Cells Successful in Preclinical Study of Spinal Cord Injury

Mon, 14 Nov 2011 08:00:00 GMT

Transplanted neural stem cells (NSCs) developed by Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development were successful in treating rats with spinal cord injury (SCI). The research conducted by Ivan Cheng, M.D., Assistant Professor in the Department of Orthopedic Surgery, Stanford University School of Medicine, was presented at the North American Spine Society Annual Meeting in Chicago, IL on November 2, 2011.

(PRWeb November 14, 2011)

Read the full story at http://www.prweb.com/releases/stemedica-preclinical/stem-cells-neural-spinal/prweb8960459.htm

Stemedica Completed Enrollment In First Cohort Of Patients With Ischemic Stroke Utilizing Allogeneic Mesenchymal Stem Cells

Fri, 21 Oct 2011 07:00:00 GMT

Stemedica Cell Technologies Inc. announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first cohort of patients in an ischemic stroke study conducted at the University of California, San Diego (UCSD).

(PRWeb October 21, 2011)

Read the full story at http://www.prweb.com/releases/stem-cell-stroke/clinical-trial-ucsd/prweb8896632.htm

Stemedica Receives Approval From UCSD To Initiate Ischemic Stroke Study With Adult Allogeneic Stem Cells

Thu, 17 Feb 2011 13:00:00 GMT

Stemedica announced today that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) to initiate a Stemedica clinical study entitled, "A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke".

(PRWeb February 17, 2011)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/ucsd-stroke/prweb5081474.htm

Stemedica International Announces Joint Venture with AnC Bio Group

Tue, 05 Oct 2010 12:00:00 GMT

The new venture, StemedicaAnC, will manufacture stem cells developed by Stemedica for the treatment of ischemic stroke, degenerative retinal and neural disorders. The initial manufacturing capacity of this alliance will produce enough product to meet the Company’s five-year revenue projections, with an expansion capacity to manufacture multiple stem cell products to meet the anticipated long-term growth of the international market for stem cells.

(PRWeb October 05, 2010)

Read the full story at http://www.prweb.com/releases/stemedica-ancbio/stem-cell-manufacture/prweb4607554.htm

Stemedica Announces Completion of Clinical Stem Cell Master Bank

Tue, 14 Sep 2010 11:00:00 GMT

Stemedica announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells. The master cell bank was manufactured in accordance with FDA Good Manufacturing Practices (cGMP). The master bank together with its parent bank has the capacity to treat up to 300,000 patients participating in approved clinical trials.

(PRWeb September 14, 2010)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cell/clinical-master-bank/prweb4512234.htm

Stemedica Announces the Appointment of Dr. César Amescua Garcia as Medical and Regulatory Affairs Director – Latin America

Thu, 24 Jun 2010 08:00:00 GMT

Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

(PRWeb June 24, 2010)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/human-clinical-trials/prweb4185804.htm

Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer

Fri, 11 Jun 2010 08:05:00 GMT

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWeb June 11, 2010)

Read the full story at http://www.prweb.com/releases/stemedica-allogeneic/adult-stem-cells/prweb4122174.htm

FDA Approves Stemedica IND Application for Ischemic Stroke Clinical Trial

Tue, 20 Apr 2010 19:22:24 GMT

Stemedica Cell Technologies, Inc. (Stemedica) announced that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).

(PRWeb April 20, 2010)

Read the full story at http://www.prweb.com/releases/stemedica-IND/Stroke-StemCell/prweb3902694.htm

Prominent Health Care Executive Joins Stemedica Board Of Directors

Tue, 01 Dec 2009 08:05:00 GMT

Anthony M. Marlon, MD was elected to the Stemedica Cell Technologies, Inc. (“Stemedica”) Board of Directors at the Company’s November 20th Board Meeting.

(PRWeb December 01, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-board/anthony-marlon/prweb3281184.htm

Stemedica President Invited To Lecture At The University Of Oxford

Thu, 12 Nov 2009 08:01:00 GMT

Nikolai Tankovich, MD, Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies, Inc. was invited to lecture at a multi-disciplinary seminar at the Centre for Science and Society at Trinity College, a constituent college of the University of Oxford, England. The seminar, which focused on current research and medical applications for stem cells, was attended by more than 300 professors and staff representing all facets of the University.

(PRWeb November 12, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-presents/oxford-stem-cell-trials/prweb3196604.htm

Stemedica Completes Meeting with the FDA

Thu, 15 Oct 2009 12:00:00 GMT

Stemedica Cell Technologies, Inc. announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. Based on a meeting October 13, 2009 with the FDA, Stemedica is planning to file an IND application in the first quarter of 2010.

(PRWeb October 15, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cell/ischemic-stroke-FDA/prweb3053264.htm

Stemedica's President Delivers Keynote Address At Swiss-Russian Forum

Thu, 17 Sep 2009 07:01:00 GMT

Dr. Nikolai Tankovich, President of Stemedica, delivered the keynote speech at the Crossing Visions Summit held in Moscow from September 14th - 16th. His presentation at a forum of top Russian and Swiss political, economic and business leaders featured advances in stem cell technology.

(PRWeb September 17, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-president/keynote-stem-cell/prweb2897234.htm

United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy

Tue, 08 Sep 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, has filed a patent application with the United States Patent and Trademark Office ("USPTO") for a proprietary methodology in the treatment for Diabetic Retinopathy. The patent application was published by the USPTO on August 27th of this year. The application is supported by extensive data and results from patients treated within a Clinical Study conducted outside of the United States beginning in January of 2006.

(PRWeb September 08, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cell/diabetic-retinopathy/prweb2839014.htm

The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010

Mon, 07 Sep 2009 07:00:00 GMT

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica's wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony took place at the European Burns Association Congress in Lausanne, Switzerland.

(PRWeb September 07, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-jordan/burn-stem-cell-trial/prweb2838964.htm

Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells

Tue, 01 Sep 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc., ("Stemedica"), a leader in adult stem cell research and manufacturing, announced today that it has been granted a license by the State of California's Food & Drug Branch to manufacture stem cells for human clinical trials. This Drug Manufacturing License recognizes Stemedica as being compliant with California law and the applicable provisions of the Code of Federal Regulations.

(PRWeb September 01, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-cGMP-stem-cell/manufacturing-license/prweb2817054.htm

Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries

Thu, 27 Aug 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit.

(PRWeb August 27, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-research/world-stem-cell-summit/prweb2793034.htm

Stemedica Requests Pre-IND Meeting With FDA

Fri, 21 Aug 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

(PRWeb August 21, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-Stroke/PRE-IND-FDA/prweb2776804.htm

Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration

Wed, 01 Jul 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc., a leader in the manufacturing and development of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium.

(PRWeb July 01, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/Retinitis-Pigmentosa/prweb2592164.htm

Stemedica Expands Globally With International Headquarters In Switzerland

Thu, 09 Apr 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, announced today the expansion of its global presence with the formation of Stemedica International S.A. headquartered in the Biopôle Technology and Business Park located in Epalinges, Switzerland near Lausanne.

(PRWeb April 09, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-international/biopole-switzerland/prweb2311934.htm

Renowned Stem Cell Researcher Files Study Results With Stemedica

Wed, 18 Mar 2009 07:01:00 GMT

Stemedica Cell Technologies, Inc. received the results today from a Stemedica-sponsored clinical study conducted by renowned stem cell researcher and clinician Professor Philippe Hernigou, MD, Ph.D. The clinical study of non-union bone injuries using autologous stem cells, allogeneic stem cells and comparative traditional treatment therapies, indicated that the use of adult stem cells provided greater healing capability in a shorter period of time with less infection than traditional therapies.

(PRWeb March 18, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-bone-study/adult-stem-cells-hernigou/prweb2244794.htm

Stemedica Announces the Appointment of Carl Bullen as Director of Manufacturing

Thu, 05 Mar 2009 08:01:00 GMT

Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Carl Bullen as Director of Manufacturing. Mr. Bullen will be responsible for manufacturing systems and procedures at Stemedica's San Diego-based manufacturing facility that is built to cGMP standards and is currently pending FDB license.

(PRWeb March 05, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-adult-stem-cell/manufacturing-director/prweb2209074.htm

CIRM Completes Briefing Visit to Stemedica Cell Technologies

Mon, 02 Mar 2009 08:01:00 GMT

Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

(PRWeb March 02, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-adult-stem-cell/CIRM-briefing-visit/prweb2196554.htm

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Fri, 27 Feb 2009 08:01:00 GMT

Stemedica provides its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

(PRWeb February 27, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-warning/plos-medicine-tumor/prweb2190414.htm

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Wed, 25 Feb 2009 08:01:00 GMT

Stemedica Cell Technologies, Inc. announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials.

(PRWeb February 25, 2009)

Read the full story at http://www.prweb.com/releases/Stemedica-Adult-Stem-Cell/Manufacturing-License/prweb2184134.htm

Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International

Fri, 13 Feb 2009 08:01:00 GMT

Stemedica Cell Technologies, Inc., a leader in adult stem cell development, today announces that it has appointed Riccardo Nisato, MBA, PhD, as Director of Manufacturing and Clinical Business Development of Stemedica International, CH. Dr. Nisato will be responsible for replicating Stemedica's U.S. based operations to Stemedica's International's center based in Lausanne, Switzerland.

(PRWeb February 13, 2009)

Read the full story at http://www.prweb.com/releases/stemedica-international/dr-nisato/prweb2036044.htm

Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services

Fri, 30 Jan 2009 08:01:00 GMT

(PRWeb January 30, 2009)

Read the full story at http://www.prweb.com/releases/stemedica/adult-stem-cell-research/prweb1936934.htm

Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors

Mon, 26 Jan 2009 08:01:00 GMT

Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).

(PRWeb January 26, 2009)

Read the full story at http://www.prweb.com/releases/2009/01/prweb1907844.htm